He Jiankui plans gene editing for Alzheimer’s after prison term

Chinese scientist He Jiankui, who served time in prison for creating the world’s first gene-edited babies, now intends to pursue similar work to combat Alzheimer’s disease. He has criticized Silicon Valley’s efforts in the field as a “Nazi eugenic experiment.” This development revives ethical debates in biotechnology.

In 2018, He Jiankui made headlines by announcing at a scientific conference in Hong Kong that he had produced the world’s first gene-edited babies. The soft-spoken researcher confirmed the reports amid a tense atmosphere in the packed auditorium, adjusting his microphone before addressing the audience.

His actions led to his imprisonment in China for violating regulations on gene editing. Now, years later, He Jiankui is preparing to resume such experiments, this time targeting Alzheimer’s disease with the goal of eradicating it.

He has voiced strong objections to ongoing projects in Silicon Valley, labeling them a “Nazi eugenic experiment.” This perspective underscores the ongoing ethical tensions surrounding gene-editing technologies like CRISPR, which He pioneered in his controversial work.

The announcement, detailed in a recent Wired article, highlights the persistent global divide on the boundaries of genetic intervention. While He’s past work sparked international condemnation for ethical lapses, his renewed ambitions signal a bold push forward in medical applications, though under heightened scrutiny.

Articoli correlati

Scientists at Virginia Tech using CRISPR tools to improve memory in aged rats, illustrating potential for combating cognitive decline.
Immagine generata dall'IA

Virginia Tech team improves memory in aged rats with targeted gene-editing

Riportato dall'IA Immagine generata dall'IA Verificato

Scientists at Virginia Tech report that tuning specific molecular pathways with CRISPR-based tools improved memory in older rats across two peer‑reviewed studies, pointing to possible routes for tackling age‑related cognitive decline.

Lo specialista in economia della salute Martin Morgenstern ha dichiarato in un'intervista che l'editing genetico trasformerà i trattamenti medici nelle prossime decadi. Secondo lui, tecnologie come CRISPR permetteranno di alterare geni specifici per combattere condizioni come il colesterolo alto. Questo approccio promette di essere più preciso dei farmaci tradizionali, sebbene comporti rischi intrinseci.

Riportato dall'IA

After 30 years in the United States, world-leading computational biologist Bao Zhirong has taken up a full-time position at the Southern University of Science and Technology in Shenzhen. Renowned for his cancer genomics research, he will study brain circuits for insights into autism at his new lab. The move underscores the appeal of China's research environment.

Researchers at UNSW Sydney and St. Jude Children’s Research Hospital report a CRISPR-derived “epigenome editing” approach that turns genes on by removing DNA methylation marks rather than cutting DNA. In cell-based experiments, they show that promoter methylation can directly—and reversibly—silence fetal globin genes, a finding they say helps settle a long-running debate about whether methylation is causal or merely correlated with gene shutdown. The work points to a potential path toward safer therapies for sickle cell disease by reactivating fetal hemoglobin without creating DNA breaks.

Riportato dall'IA

Researchers at Texas A&M University have developed a chemogenetic system that uses caffeine to activate CRISPR gene editing in cells, potentially aiding treatments for cancer and diabetes. The method allows precise control over gene modifications by consuming small amounts of caffeine from everyday sources like coffee or chocolate. This approach aims to enhance immune responses and insulin production with reversible activation.

A new book by bioethicist Daphne O. Martschenko and sociologist Sam Trejo explores the implications of polygenic scores in genetic testing, highlighting potential inequalities and myths surrounding genetics. Through their 'adversarial collaboration,' the authors debate whether such research can promote equity or entrench social divides. They call for stricter regulation to ensure responsible use.

Riportato dall'IA

Rising talent in micron-precision 3D printing, Xu Zhenpeng, announced on social media his move from a California startup to an academic position in Shanghai, China. Previously, he led a team developing 3D printing techniques to make chip production faster and cheaper than conventional multimillion-dollar machines.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta